02196nas a2200325   4500008004100000022001400041245010300055210006900158260001300227300001400240490000700254520111400261653001201375653002201387653003501409653002801444653001301472653001101485653001801496653001801514653001901532100003501551700002501586700002901611700002301640700002901663700002401692700002601716856012801742       2021                        eng d  a1432-085100aImmunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.0 aImmunotherapy in nonsmallcell lung cancer current status and fut  c2021 May  a1177-11880 v703 a<p>Immunotherapy has been one of the great advances in the recent years for the treatment of advanced tumors, with nonsmall-cell lung cancer (NSCLC) being one of the cancers that has benefited most from this approach. Currently, the only validated companion diagnostic test for first-line immunotherapy in metastatic NSCLC patients is testing for programmed death ligand 1 (PD-L1) expression in tumor tissues. However, not all patients experience an effective response with the established selection criteria and immune checkpoint inhibitors (ICIs). Liquid biopsy offers a noninvasive opportunity to monitor disease in patients with cancer and identify those who would benefit the most from immunotherapy. This review focuses on the use of liquid biopsy in immunotherapy treatment of NSCLC patients. Circulating tumor cells (CTCs), cell-free DNA (cfDNA) and exosomes are promising tools for developing new biomarkers. We discuss the current application and future implementation of these parameters to improve therapeutic decision-making and identify the patients who will benefit most from immunotherapy.</p>10aAnimals10aBiomarkers, Tumor10aCarcinoma, Non-Small-Cell Lung10aCell-Free Nucleic Acids10aExosomes10aHumans10aImmunotherapy10aLiquid Biopsy10aLung Neoplasms1 aBrozos-Vázquez, Elena, María1 aDíaz-Peña, Roberto1 aGarcía-González, Jorge1 aLeón-Mateos, Luis1 aMondelo-Macía, Patricia1 aPeña-Chilet, Maria1 aLópez-López, Rafael  uhttp://clinbioinfosspa.es/content/immunotherapy-nonsmall-cell-lung-cancer-current-status-and-future-prospects-liquid-biopsy